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Abstract
The 1-Oxo-1, 2, 3, 4-tetrahydroisoquinoline and 1-Oxo-1, 2-dihydroisoquinoline scaffolds were
utilized in the design and solution phase synthesis of focused libraries of compounds for screening
against West Nile Virus (WNV) protease. Exploratory studies have lead to the identification of a
WNV protease inhibitor (a 1-oxo-1, 2-dihydroisoquinoline-based derivative, 12j) which could
potentially serve as a launching pad for a hit-to-lead optimization campaign. The identified hit was
devoid of any inhibitory activity toward a panel of mammalian serine proteases.
Introduction
Proteases account for ~2% of the genes in humans and infectious organisms and are
involved in the regulation of a multitude of essential physiological processes. A wide range
of human diseases are associated with the aberrant activity of proteases (1–2). Furthermore,
many proteases are essential to the survival of bacterial, viral, parasitic, and fungal
pathogens.
West Nile virus (WNV), a member of the Flavivirus genus of the Flaviviridae family, has
emerged as an important mosquito-borne viral pathogen (3). No effective vaccines or
antiviral agents are currently available for the prevention or treatment of WNV (4). WNV is
a small, enveloped virus with a single-stranded, positive sense 11-kb RNA genome, which
encodes a polyprotein precursor. Co-and post-translational cleavage of the polyprotein
produces three structural (C, prM, and E) and seven nonstructural (NS1, NS2A, NS2B, NS3,
NS4A, NS4B, and NS5) proteins by a concerted action of a host signal peptidase and the
trypsin-like viral serine protease. The viral protease encoded within NS3 in conjunction with
the NS2B cofactor cleaves at NS2A-NS2B, NS2B-NS3, NS3-NS4A, and 4B-NS5 sites, as
well as some internal sites within C, NS3 and NS4A. Cleavage at these sites is essential for
viral replication. Thus, WNV NS2B/NS3 protease has emerged as an important target for the
design and development of novel therapeutics against West Nile virus (5).
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Flavivirus NS2B is an endoplasmic membrane-associated hydrophobic protein of 130 amino
acid residues (6). Active protease consists of a heterodimeric complex of NS2B and NS3.
The amino terminal part of NS3 that contains the serine protease catalytic triad is sufficient
for interaction with NS2B and activation of the protease domain. The carboxy terminal
portion of NS3 contains ATPase, RNA helicase and 5′ RNA triphosphatase activities and
performs other functions in the virus life cycle such as viral replication and 5′ capping (7–8).
The viral serine protease cofactor NS2B protein consists of three hydrophobic regions
flanking a conserved hydrophilic domain of 45 amino acid residues. For the function of the
viral protease in infected host cells, the hydrophobic regions of NS2B as well as the
hydrophilic domain are required (7), however, the latter domain alone is sufficient for the
interaction with the NS3 protease domain and for in vitro protease activity in cleaving the
polyprotein substrate at specific sites. These sites contain two basic amino acid residues at
the P1 and P2 positions (9) followed by a residue with a short side chain (Ala, Ser, or Gly) at
the P1′ position (6,10–12).
The substrate specificity of WNV protease has been probed using peptidyl substrates and
inhibitors (4(b), 12–13) and X-ray crystallography. The active site of WNV NS2B/NS3
protease, consisting of His51, Asp75 and Ser135, is located at the interface of the N- and C-
terminal lobes and prefers a dibasic motif at P1-P2 (14). X-ray crystal structures of WNV
NS2B-NS3pro complexed to aprotinin (Bowman Pancreatic Trypsin Inhibitor (BPTI) (15)
and Bz-Nle-Lys-Arg-Arg-CHO (16), respectively, have been reported. Inhibitors of WNV
protease containing a highly charged peptidyl or non-peptidyl recognition component
reflecting the substrate specificity of the protease include peptidyl aldehydes (17), D-Arg-
based peptides (18), and guanidine-based compounds (19). Other low molecular weight
inhibitors of the protease include pyrazoline (20) and sultam thiourea (21) derivatives and
others (22). There is currently a need for low molecular weight non-peptidyl agents that
exhibit superior potency, selectivity and drug-like characteristics. We report herein the
results of preliminary studies related to the use of 1-oxo-1, 2, 3, 4-tetrahydroisoquinoline




The biochemical rationale underlying the use of the 1-oxo-1, 2, 3, 4-tetrahydroisoquinoline
scaffold in the design of serine protease inhibitors rested on the following considerations: (a)
previous studies related to the steric course and specificity of α-chymotrypsin-catalyzed
reactions have shown that D-1-oxo-1, 2, 3, 4-tetrahydroisoquinoline 3-carboxymethyl ester
(Figure 1(a)) behaves as a relatively efficient substrate of the enzyme, indicating that the
heterocyclic scaffold is capable of binding productively to the active site of the enzyme (23);
(b) WNV NS2B-NS3pro is a trypsin-like serine protease with a prototypical catalytic triad
and an active site that is located at the interface of the N- and C-terminal lobes. We reasoned
that an entity such as (I) (Figure 1) that embodied a recognition element (1-oxo-1, 2, 3, 4-
tetrahydroisoquinoline scaffold) and a suitably-positioned serine trap may function as a non-
peptidyl transition state inhibitor of the viral protease (Figure 1(b)) (24). Of particular
interest were the α-ketoamide derivatives (structure (I), Z = CONHR), since judicious
changes in the nature of the R group could potentially lead to the exploitation of additional
favorable binding interactions.
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We initially set out to prepare aldehyde 3 from compound 2 (Scheme 1) since it would serve
as a suitable intermediate for synthesizing the desired inhibitors. Thus, when compound 2
was treated with DIBAL (25) only the starting material was recovered. An alternative
method for making 3, also unsuccessful, involved the treatment of 2 with
iodotrimethylsilane in methylene chloride to give the corresponding trimethylsilyl ether
(RCOOSi(CH3)3) which was then treated with DIBAL, as described in the literature (26).
Lithium aluminum hydride reduction of ester 2 in the presence of diethylamine (27) failed to
give 3 and gave instead the corresponding alcohol. A second approach toward the synthesis
of 3 was pursued which involved reduction of 2 (LiBH4/THF) to give alcohol 4 followed by
treatment with pyridinium chlorochromate in methylene chloride (28). NMR analysis of the
complex reaction mixture showed the absence of any aldehyde, despite complete
consumption of the starting alcohol. Swern oxidation of 4 yielded a white solid the structure
of which was established by X-ray crystallography to be that of compound 5. It is evident
that aldehyde 3 is formed which then dimerizes to 5 under the reaction conditions. Further
attempts to generate variants of (I), such as the direct formation of (I) with Z = heterocycle
(29), were also unsuccessful and necessitated a change in strategy that entailed the solution-
phase generation of a library of compounds based on the 1-oxo-1, 2, 3, 4-
tetrahydroisoquinoline scaffold that could potentially function as reversible competitive
inhibitors of the enzyme. Thus, the synthesis of compounds 7(a–f) proceeded uneventfully
when aliphatic amines were used (Scheme 2 (a)), however, an alternative route was utilized
in the synthesis of compounds 7(g–j) derived from aromatic amines (Scheme 2 (b)). The
unusually low yields are probably due to steric effects, the use of non-optimized conditions,
and loss of sample during the purification of the compounds. A fairly diverse set of amine
inputs (Table 1) was utilized for optimal space exploration. With the exception of compound
7g (~25% inhibition at 50 μM inhibitor concentration), the rest of the compounds were
devoid of any inhibitory activity against WNV protease, suggesting that these compounds do
not engage in multiple binding interactions with the target enzyme. This series of
compounds was inactive against a representative panel of serine proteases, including bovine
α-chymotrypsin, human neutrophil elastase, cathepsin G, and human skin chymase (30).
Intriguingly, compounds 7f and 7h were found to inhibit bovine trypsin (42% and 22%
inhibition, respectively, at a 50 μM inhibitor concentration).
The exploratory studies cited above suggested that the non-planar component in (I) may be
inimical to binding, consequently a focused library of compounds (10c, 10f, 12a–c, 12f, 12j)
was generated based on the 1-oxo-1, 2-dihydroisoquinoline scaffold and its bromo variant
using Scheme 3. Screening of these libraries resulted in the identification of a hit (compound
12j) that was found to be a fair inhibitor of WNV protease (IC50 30 μM). A plausible mode
of binding of energy-minimized compound 12j to the active site of the enzyme is illustrated
in Figure 2(a–b). The aromatic portion of the bromisoquinoline moiety forms a π-stacking
interaction with Y161 and engages in end-on hydrophobic interactions with Y150. The
amide on the bromoisoquinoline group hydrogen bonds with the hydroxyl side chain of the
catalytic S135, namely, the carbonyl oxygen on bromoisoquinoline serves as a hydrogen
acceptor from the S135 proton and the amide proton serve as hydrogen bond donor to the
S135 hydroxyl oxygen. The amide proton on the linker between the bromoisoquinoline and
the (m-phenoxy) phenyl is predicted to hydrogen bond with the backbone carbonyl of G151.
The first aromatic ring in the (m-phenoxy)phenyl group is solvent exposed and is not
predicted to participate in any significant favorable interactions. However, the second
aromatic ring interacts with the side chain of V72, with the mildly hydrophobic β carbons of
His51 and D75, and has an end-on hydrophobic interaction with W50. Although the
aromatic portion of the bromoisoquinoline moiety engages in π-stacking interactions and fits
well within a very small cavity, it might be possible to improve the affinity for this cavity by
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noting that the end of the ring points toward highly polar species, such as the D129 side
chain and the Y130 backbone. Furthermore, the first aromatic ring in the (m-
phenoxy)phenyl component serves as a semi rigid spacer of ideal length for fostering the
favorable interactions associated with the bromoisoquinoline ring and on the second
aromatic ring in the (m-phenoxy)phenyl component. Consequently, exploring other groups
that maintain the same spacer distance and orientation may provide additional opportunities
for affinity enhancement.
In summary, exploratory studies utilizing the 1-oxo-1, 2-dihydroisoquinoline scaffold have
led to the identification of an inhibitor of WNV protease suitable for further exploration.
Experimental Section
General
The 1H NMR spectra were recorded on a Varian XL-300 or XL-400 NMR spectrometer. A
Gemini EM microplate spectrofluorometer (Molecular Devices Corporation, Sunnyvale,
CA) was used in the enzyme assays and inhibition studies. Melting points were determined
on a Mel-Temp apparatus and are uncorrected. Reagents and solvents were purchased from
various chemical suppliers (Aldrich, Acros Organics, TCI America, and Bachem). Silica gel
(230–450 mesh) used for flash chromatography was purchased from Sorbent Technologies,
Atlanta, GA. Thin layer chromatography was performed using Analtech silica gel plates.
The TLC plates were visualized using iodine and/or UV light. WNV protease was expressed
in E. coli as described for Dengue virus-2 protease (12) and was purified as previously
described (14). Boc-Gly-Lys-Arg-AMC was purchased from Bachem. The purity of all
compounds was established by TLC. HPLC analyses were performed on a Varian Prostar
320 monitored at 280 nm using a C18 Luna2 250 × 4.6 mm column with an isocratic 45%
acetonitrile and 55% aqueous solution containing 5% methanol and 0.1% formic acid.
Synthesis
(DL)Methyl 2-isocyanato-3-phenylpropanoate 1—DL-phenylalanine methyl ester
hydrochloride (13.6 g; 63 mmol) was placed in a round bottom flask and pumped under high
vacuum overnight. Dioxane (150 mL) was then added, followed by trichloromethyl
chloroformate (10.5 mL; 88.5 mmol). The resulting mixture was refluxed gently overnight.
The solvent was removed and the residue was distilled under reduced pressure to give the
corresponding isocyanate 1 as a colorless oil (12.9 g, 99% yield). 1H NMR (CDCl3) δ 3.03
(dd, J = 13.7, 5.0 Hz, 1H), 3.16 (dd, J = 13.7, 8.2 Hz, 1H), 3.81(s, 3H), 4.02–4.10 (m, 1H),
7.18–7.38 (m, 5H).
(DL)Methyl 1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 2—To a solution
of compound 1 (12.9 g; 63 mmol) in dry methylene chloride (120 mL) was added AlCl3
(16.8 g; 126 mmol) in small portions and the resulting mixture was refluxed for 2 h. The
reaction mixture was allowed to cool to room temperature and then placed in an ice-water
bath. Water (100 mL) was slowly added and the mixture was stirred for 30 minutes. The two
layers were separated and the organic layer was dried over anhydrous sodium sulfate.
Removal of the solvent left a crude product which was purified by flash chromatography
(silica gel/ethyl acetate/hexanes) to give compound 2 as a white solid (9.2 g; 71% yield), mp
98–100 °C. 1H NMR (CDCl3) δ 3.22 (dd, J = 15.7, 5.7 Hz, 1H), 3.34 (dd, J = 15.7, 9.4 Hz,
1H), 3.80 (s, 3H), 4.40–4.46 (m, 1H), 6.65 (s, 1H), 7.23 (d, J = 6.9 Hz, 1H), 7.38 (t, J = 7.6
Hz, 1H), 7.46 (t, J =7.6 Hz, 1H), 8.08 (d, J = 6.9 Hz, 1H); HRMS (ESI) calcd for
C11H12NO3 [M+H]+ 206.0817, found 206.0811; C11H11NO3Na [M+Na]+ 228.0637, found
228.0642.
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(DL)3-(Hydroxymethyl)-3,4-dihydroisoquinolin-1(2H)-one 4—To a solution of
compound 2 (4.1 g; 20.0 mmol) in dry THF (20 mL) was added dropwise a solution of 2M
LiBH4 in THF (10 mL; 20.0 mmol), followed by the dropwise addition of 60 mL absolute
ethanol. The reaction was stirred at room temperature overnight. The reaction mixture was
cooled in an ice-bath and the pH was adjusted to 4 by adding 5% HCl. The solvent was
removed and the residue was treated with water (60 mL) and extracted with ethyl acetate (3
× 50 mL). The combined organic extracts were dried over anhydrous sodium sulfate.
Removal of the solvent left compound 4 as a colorless oil (3.2 g, 90% yield). 1H NMR
(CDCl3): δ 2.91 (d, J = 7.0 Hz, 2H), 3.70 (dd, J = 11.4, 4.7 Hz, 1H), 3.85 (dd, J = 11.4, 7.7
Hz, 1H), 3.85–3.96 (m, 1H), 7.20–7.48 (m, 4H), 8.02–8.05 (d, J = 7.0 Hz, 1H); HRMS (ESI)
calcd for C10H12NO2 [M+H]+ 178.0868, found 178.0859; C10H11NO2Na [M+Na]+
200.0687, found 200.0699.
6,13-Dihydroxy-5,5a,6a,7,12,12a,13a,14-octahydrodinaphtho[2,3-a,d]-
hexahydropyrazine-7,14-dione 5—A solution of 2M oxalyl chloride in CH2Cl2 (2.75
mL, 5.5 mmol) and 12 mL CH2Cl2 were placed in a 50 mL three-neck round bottom flask
equipped with a thermometer, a CaCl2 drying tube and two pressure-equalizing dropping
funnels containing DMSO (0.85 mL; 11 mmol) in 2.5 mL CH2Cl2 and compound 4 (0.88 g;
5 mmol) in 5 mL CH2Cl2 and 1 mL DMSO, respectively. The DMSO solution was added to
the stirred oxalyl chloride solution at −50~−60 °C. After stirring for 2 minutes, the solution
containing compound 4 was added over 5 minutes and the mixture was stirred for an
additional 15 minutes. Triethylamine (3.5 mL; 25 mmol) was added and the reaction mixture
was stirred for 5 minutes and allowed to warm to room temperature for 3.5 h. Water (25 mL)
was added and the two layers were separated. The aqueous layer was extracted with
additional CH2Cl2 (25 mL) and the combined organic extracts were washed with brine (25
mL) and dried over anhydrous sodium sulfate. Removal of the solvent left a crude product
which was purified by flash chromatography (silica gel/ethyl acetate/hexanes) to give
compound 5 (150 mg; 8% yield) as a white solid, mp 154–156 °C. 1H NMR (DMSO-D6): δ
3.18 (dd, J = 16.6, 3.9 Hz, 2H), 3.44 (dd, J = 16.6, 6.4 Hz, 2H), 3.91 (t, J = 7.1 Hz, 2H), 4.08
(s, 2H), 5.51 (d, J = 7.6 Hz, 2H), 7.30–7.42 (m, 4H), 7.50–7.60 (t, J = 6.3 Hz, 2H), 7.79–
7.83 (d, J = 6.7 Hz, 2H).
(DL)1-Oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 6—To a chilled
solution of compound 2 (3.0 g; 14.7 mmol) in 30 mL THF was added 15 mL of 1 M lithium
hydroxide and the reaction mixture was stirred in an ice-bath for 30 minutes. The solvent
was removed on the rotary evaporator and the residue treated with water (30 mL). The
solution was extracted with 50 mL ethyl acetate. The aqueous solution was acidified to pH
2, yielding a white precipitate which was collected by suction filtration and air dried to yield
a white solid (2.1 g; 75% yield), mp 224–226 ° C. 1H NMR (CD3OD) δ 3.29 (dd, J = 14.3,
5.9 Hz, 1H), 3.42 (dd, J = 14.3, 5.9 Hz, 1H), 4.40 (t, J = 5.6 Hz, 1H), 7.30–7.55 (m, 3H),
7.97 (d, J = 7.8 Hz, 1H); HRMS (ESI) calcd for C10H9NO3Na [M+Na]+ 214.0480, found
214.0465.
General procedure for amide 7(a–f) formation
A solution of acid 6 (0.38 g; 2 mmol) in dry N, N-dimethylformamide (5 mL) was treated
with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.38 g; 2 mmol),
followed by the appropriate amine (2 mmol). The reaction mixture was stirred at room
temperature overnight. The solvent was removed in vacuo and ethyl acetate (50 mL) was
added to the residue. The organic layer was washed with 5% aqueous HCl (2 × 10 mL),
saturated aqueous NaHCO3 (2 × 10 mL), and brine (10 mL). The organic layer was dried
over anhydrous sodium sulfate, the solvent was removed on the rotary evaporator, and the
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crude product was purified using flash chromatography (silica gel/ethyl acetate/hexanes) to
give the corresponding amide 7a–f.
(DL)N-(3-Methoxyphenethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide 7a—White solid (10% yield), mp 124–126 °C. 1H NMR (CDCl3) δ 2.60–
2.72 (m, 2H), 3.20–3.30 (dd, J = 15.1, 4.4 Hz, 1H), 3.25–3.55 (m, 3H), 3.72 (s, 3H), 4.23 (q,
J = 3.2 Hz, 1H), 6.52–6.72 (m, 3H), 7.02–7.50 (m, 5H), 7.60 (d, J = 2.9 Hz, 1H), 7.95 (d, J =
6.9 Hz, 1H); HRMS (ESI) calcd for C19H21N2O3 [M+H]+ 325.1552, found 325.1547;
C19H20N2O3Na [M+Na]+ 347.1372, found 347.1364.
(DL)N-(2-Morpholinoethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide 7b—White solid (26% yield), mp 138–140 °C. 1H NMR (CD3OD) δ 2.28–
2.52 (m, 6H), 3.20–3.38 (m, 2H), 3.60 (t, J = 5.0 Hz, 4H), 3.72(s, 2H), 4.26 (t, J = 5.6 Hz,
1H), 7.27 (d, J = 6.9 Hz, 1H), 7.35 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.92 (d, J =
6.9 Hz, 1H); HRMS (ESI) calcd for C16H22N3O3 [M+H]+ 304.1661, found 304.1652.
(DL)N-(Furan-2-ylmethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
7c—White solid (57% yield), mp 157–158 °C. 1H NMR (CDCl3) δ 3.30 (dd, J = 15.6, 5.2
Hz, 1H), 3.43 (dd, J = 15.6, 5.2 Hz, 1H), 4.26–4.33 (m, 1H), 4.32 (dd, J = 14.3, 5.8 Hz, 1H),
4.46 (dd, J = 14.3, 5.8 Hz, 1H), 6.01 (d, J = 1.9 Hz, 1H), 6.22–6.24 (m, 1H), 6.55 (s, 2H),
7.20–7.55 (m, 4H), 7.99–8.02 (d, J = 5.9 Hz, 1H); HRMS (ESI) calcd for C15H15N2O3 [M
+H]+ 271.1083, found 271.1068; C15H14N2O3Na [M+Na]+ 293.0902, found 293.0894.
(DL)N-(2,2-Diphenylethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
7d—White solid (23% yield), mp 166–168 °C. 1H NMR (CDCl3) δ 3.16 (dd, J = 16.9, 5.8
Hz, 1H), 3.34 (dd, J = 16.9, 6.8 Hz, 1H), 3.65–3.80 (m, 1H), 3.85–4.00 (m, 1H), 4.00–
4.12(m, 1H), 4.12–4.20 (m, 1H), 4.58 (s, 1H), 4.68 (s, 1H), 6.98–7.52 (m, 13H), 7.85–7.92
(d, J = 9.4 Hz, 1H); HRMS (ESI) calcd for C24H23N2O2 [M+H]+ 371.1760, found 371.1761;
C24H22N2O2Na [M+Na]+ 393.1579, found 393.1580.
(DL)N-Hexyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 7e—White
solid (24% yield), mp 99–101°C. 1H NMR (CDCl3) δ 0.79 (t, J = 7.3 Hz, 3H), 1.09–1.20
(m, 2H), 1.30–1.41(m, 2H), 3.18–3.23 (m, 2H), 3.31 (dd, J = 13.9, 5.0 Hz, 1H), 3.45 (dd, J =
13.9, 5.0 Hz, 1H), 4.26 (q, J = 3.8 Hz, 1H), 6.62 (s, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.36 (t, J =
7.8 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.52 (s, 1H), 7.98 (d, J = 8.3 Hz, 1H); HRMS (ESI)
calcd for C14H18N2O2Na [M+Na]+ 269.1266, found 269.1276; C14H18N2O2K [M+K]+
285.1005, found 285.1012.
(DL) N-Benzyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 7f—White
solid (110 mg; 20% yield), mp 165–167 °C. 1H NMR (CDCl3) δ 3.30 (dd, J = 15.8, 6.2 Hz,
1H), 4.46 (dd, J = 15.8, 6.2 Hz, 1H), 4.26 (t, J = 3.4 Hz, 1H), 4.31 (dd, J = 13.5, 5.1 Hz, 1H),
4.44 (dd, J = 13.5, 5.1 Hz, 1H), 6.82 (s, 1H), 6.89–7.54 (m, 9H), 7.91 (d, J = 7.4 Hz, 1H);
HRMS (ESI) calcd for C17H17N2O2 [M+H]+ 281.1290, found 281.1275; C17H16N2O2Na
[M+Na]+ 303.1109, found 303.1097.
General procedure for N-Boc/N-Cbz phenylalanine and aromatic amine coupling reactions
DL-N-Cbz-phenylalanine (or L-N-Boc-phenylalanine) (5 mmol) was dissolved in 10 mL
DMF and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.96 g; 5 mmol)
was added, followed by the appropriate aromatic amine (5.5 mmol). The resulting mixture
was stirred at room temperature overnight. Removal of the solvent on the rotary evaporator
left a residue which was dissolved in 50 mL ethyl acetate. The ethyl acetate solution was
washed with 5% aqueous HCl (3 × 25 mL), saturated aqueous NaHCO3 (3 × 25 mL), and
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brine (25 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent
was removed on the rotary evaporator to give pure product 8.
(DL)Tert-butyl 1-oxo-3-phenyl-1-(thiazol-2-ylamino)propan-2-yl-carbamate 8g
—White solid (63% yield), mp 88–90 °C. 1H NMR (CDCl3) δ 1.40 (s, 9H), 3.05–3.20 (m,
2H), 4.64–4.78 (m, 1H), 5.18 (s, 1H), 7.00–7.28 (m, 6H), 7.54 (d, J = 2.2 Hz, 1H), 11.20 (s,
1H); HRMS (ESI) calcd for C17H22N3O3S [M+H]+ 348.1382, found 348.1368;
C17H21N3O3Na [M+Na]+ 370.1201, found 370.1190.
(DL)Benzyl 1-(benzo[d][1,3]dioxol-5-ylamino)-1-oxo-3-phenylpropan-2-yl-
carbamate 8h—White solid (48% yield), mp 145–147 °C. 1H NMR (CDCl3) δ 3.02–3.20
(m, 2H), 4.50 (q, J = 7.8 Hz, 1H), 5.05 (s, 2H), 5.50 (s, 1H), 5.92 (s, 2H), 6.61 (dd, J = 36.5,
7.2 Hz, 2H), 7.03 (s, 1H), 7.18–7.37 (m, 10H), 7.55 (s, 1H); HRMS (ESI) calcd for
C24H23N2O5 [M+H]+ 419.1607, found 419.1594; C24H22N2O5Na [M+Na]+ 441.1426,
found 441.1412.
(DL)Benzyl 1-(4-morpholinophenylamino)-1-oxo-3-phenylpropan-2-yl-
carbamate 8i—White solid (87% yield), mp 200–202 °C. 1H NMR (CDCl3) δ 3.05–3.22
(m, 6H), 3.85 (t, J = 4.3 Hz, 4H), 4.51 (q, J = 5.9 Hz, 1H), 5.08 (s, 2H), 5.48 (s, 1H), 6.80
(dd, J = 9.4 Hz, 2H), 7.18–7.38 (m, 12H), 7.40 (s, 1H); HRMS (ESI) calcd for C27H30N3O4
[M+H]+ 460.2236, found 460.2198; C27H29N3O4Na [M+Na]+ 482.2056, found 482.2047.
(DL)Benzyl 1-oxo-1-(3-phenoxyphenylamino)-3-phenylpropan-2-ylcarbamate
8j—White solid (100% yield), mp 132–134 °C. 1H NMR (CDCl3) δ 3.02–3.20 (m, 2H),
4.45–4.58 (m, 1H), 5.05 (s, 2H), 5.48 (s, 1H), 6.37–6.42 (m, 1H), 6.70–6.75 (m, 1H), 6.98–
7.37 (m, 19H), 7.68 (s, 1H); HRMS (ESI) calcd for C29H27N2O4 [M+H]+ 467.1971, found
467.1963; C29H26N2O4Na [M+Na]+ 489.1790, found 489.1777.
(DL)1-Oxo-N-(thiazol-2-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 7g—
Compound 8g (1.14 g; 3.28 mmol) was dissolved in 15 mL trifluoroacetic acid at room
temperature. The reaction mixture was stirred for 30 minutes and the trifluoroacetic acid was
removed under vacuum. Water (5 mL) was added and the pH was adjusted to 9 using a
saturated solution of sodium carbonate. The free amine was extracted with 50 mL ethyl
acetate and the organic layer was dried using anhydrous sodium sulfate. Removal of the
solvent left a colorless oil (0.60 g; 74% yield). The oil was dissolved in 10 mL dioxane, and
trichloromethyl chloroformate (0.4 mL; 3.4 mmol) was added. The resulting mixture was
stirred at room temperature overnight. Removal of the solvent under vacuum left a residue
which was dissolved in methylene chloride (20 mL). Aluminum chloride (0.64 g; 4.8 mmol)
was added and the resulting mixture was refluxed for 1h. The reaction mixture was allowed
to cool to room temperature and water (10 mL) was slowly added. The mixture was stirred
for 30 minutes and then transferred to a separatory funnel. The organic layer was washed
with water (2 × 15 mL) and dried over anhydrous sodium sulfate. Removal of the solvent
gave a pure product 7g (50 mg; 6% yield) as a gray solid, mp 202–204 °C. 1H NMR
(CDCl3) δ 2.96 (dd, J = 13.2, 9.0 Hz, 1H), 3.45 (dd, J = 12.0, 2.4 Hz, 1H), 4.40–4.48 (m,
1H), 5.58 (s, 1H), 7.20–7.38 (m, 6H), 7.77 (d, J = 1.3 Hz, 1H); HRMS (ESI) calcd for
C13H12N3O2S [M+H]+ 274.0650, found 274.0659; C13H11N3O2SNa [M+Na]+ 296.0470,
found 296.0468.
Representative procedure for the synthesis of compounds 7h-j
(DL)N-(Benzo[d][1,3]dioxol-5-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide 7h—Compound 8h (1.0 g; 2.39 mmol) was dissolved in 50 mL ethyl
acetate, then 10% palladium/carbon(0.33 g) wetted with 2 mL ethyl acetate was added. The
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mixture was placed on a Parr hydrogenator, 20 psi hydrogen gas was applied and the
mixture was shaken for 3 h. The reaction mixture was gravity filtered and the filtrate was
evaporated to give a brown oil (0.5g; 74% yield) which was dissolved in 8 mL 1, 4-dioxane
and treated with trichloromethyl chloroformate (0.3 mL; 2.5 mmol). The resulting mixture
was stirred at room temperature overnight. The solvent was removed under vacuum and the
residue was taken up in methylene chloride (15 mL). Aluminum chloride (0.48 g; 3.6 mmol)
was added and the resulting mixture was refluxed for 1 h and allowed to cool to room
temperature. After water (15 mL) was slowly added, the reaction mixture was stirred for 30
minutes and then transferred to a separatory funnel. The organic layer was washed with
water (2 × 15 mL) and dried over anhydrous sodium sulfate. Removal of the solvent left a
crude product which was purified by flash chromatography (silica gel/ethyl acetate/hexanes)
to give compound 7h (120 mg; 16% yield) as a white solid, mp 120–122 °C. 1H NMR
(CDCl3) δ 3.09 (dd, J = 13.2, 3.6 Hz, 1H), 3.20 (dd, J = 13.2, 5.7 Hz, 1H), 4.35–4.40 (m,
1H), 5.95 (s, 2H), 6.50–6.59 (m, 2H), 6.81 (d, J = 7.6 Hz, 1H), 6.88 (s, 1H), 7.20–7.35 (m,
5H); HRMS (ESI) calcd for C17H15N2O4 [M+H]+ 311.1032, found 311.1037;
C17H14N2O4Na [M+Na]+ 333.0851, found 333.0840.
(DL)N-(4-(1,3-Oxazinan-3-yl)phenyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide 7i—White solid (5% yield), mp 166–168 °C. 1H NMR (CDCl3) δ 3.01–3.35
(m, 6H), 3.85 (t, J = 5.0 Hz, 4H), 4.37–4.41(m, 1H), 6.04 (s, 1H), 6.92 (d, J = 9.4 Hz, 2H),
7.05 (d, J = 9.4 Hz, 2H), 7.22–7.38 (m, 4H); HRMS (ESI) calcd for C20H22N3O3 [M+H]+
352.1661, found 352.1648; C20H21N3O3Na [M+Na]+ 374.1481, found 374.1467.
(DL)1-Oxo-N-(3-phenoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide 7j—White solid (7% yield), mp 93–95 °C. 1H NMR (CDCl3) δ 3.06 (dd, J =
10.3, 5.1 Hz, 1H), 3.27 (dd, J = 10.3, 2.5 H, 1H), 4.38–4.40 (m, 1H), 6.22 (s, 1H), 6.82–7.40
(m, 14H); HRMS (ESI) calcd for C22H19N2O3 [M+H]+ 359.1396, found 359.1398;
C22H18N2O3Na [M+Na]+ 381.1215, found 381.1219.
Methyl 1-oxo-1,2-dihydroisoquinoline-3-carboxylate 9—To a solution of compound
1-oxo-1, 2, 3, 4-tetrahydroisoquinoline 3-carboxymethyl ester 2 (13.61 g; 66 mmol) in 200
mL 1, 4-dioxane was added 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (16.0g; 70.5
mmol) and the mixture was refluxed overnight. The solvent was removed in vacuo and the
residue was taken up in 200 mL ethyl acetate and washed with 5% NaOH (2 × 50 mL). The
organic layer was dried over anhydrous sodium sulfate and the filtrate was evaporated,
leaving a crude product which was purified with flash chromatography (silica gel/ethyl
acetate/hexanes) to give compound 9 as a white solid (3.0 g; 22% yield), mp 154–155
°C. 1H NMR (CDCl3) δ 3.92 (s, 3H), 7.52–7.68 (m, 4H), 8.37–8.41 (m, 1H), 9.12 (s, 1H);
HRMS (ESI) calcd for C11H10NO3 [M+H]+ 204.0661, found 204.0664; C11H9NO3Na [M
+Na]+ 226.0480, found 226.0475.
Methyl 4-bromo-1-oxo-1,2-dihydroisoquinoline-3-carboxylate 11—To a solution
of compound 1-oxo-1, 2, 3, 4-tetrahydroisoquinoline 3-carboxymethyl ester 2 (3.56 g; 17.4
mmol) in 175 mL methylene chloride were added N-bromosuccinimide (NBS) (6.26 g; 35.2
mmol) and benzyl peroxide (0.20 g; 0.8 mmol), and the reaction was refluxed for 24 h. The
reaction was cooled down to room temperature and then washed with saturated NaHCO3 (3
× 80 mL) and brine (80 mL). The organic layer was dried over anhydrous sodium sulfate.
The drying agent was filtered and the filtrate was concentrated. The crude product was
precipitated in 30 mL ethyl acetate and filtered, yielding compound 11 as a white solid (2.84
g; 57% yield), mp 186–187 °C. 1H NMR (CDCl3) δ 4.05 (s, 3H), 7.68 (t, J = 8.1 Hz, 1H),
7.85 (t, J = 8.1 Hz, 1H), 8.27 (d, J = 6.5 Hz, 1H), 8.46 (d, J = 6.5 Hz, 1H), 9.45 (s, 1H);
HRMS (ESI) calcd for C11H9 35BrNO3 [M+H]+ 281.9766, found 281.9767; C11H9 37BrNO3
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[M+H]+ 283.9745, found 283.9744; C11H8 35BrNO3Na [M+Na]+ 303.9585, found
303.9584; C11H8 37BrNO3Na [M+Na]+ 305.9565, found 305.9569.
Hydrolysis of methyl ester 9—To a solution of ester 9 (5 mmol) in 10 mL dioxane was
added 1M lithium hydroxide (10 mL), and the reaction mixture was stirred at room
temperature for 1 h. The solvent was removed on the rotary evaporator and the residue was
treated with 20 mL water and acidified to pH 2, forming a precipitate. The precipitate was
collected by suction filtration and washed with 20 mL ethyl acetate to give the
corresponding acid as a white solid (80% yield), mp 230–232 °C. 1H NMR (DMSO-D6) δ
7.40 (s, 1H), 7.64 (t, J = 7.3 Hz, 1H), 7.79 (t, J = 7.3 Hz, 1H), 7.85 (d, J = 7.5 Hz, 1H), 8.22
(d, J = 7.5 Hz, 1 H), 11.80 (s, 1H).
The acid derived from ester 11 was obtained the same procedure as that above. White solid
(64% yield), mp > 260 °C. 1H NMR (DMSO-D6) δ 7.69 (t, J = 6.9 Hz, 1H), 7.84–8.00 (m,
2H), 8.25 (d, J = 5.3 Hz, 1H), 11.80 (s, 1H).
General coupling reaction procedure for compounds 10c, 10f, 12a, 12c, 12f and 12i-j
A solution of acid (2 mmol) derived from 9 or 11 in dry N, N-dimethylformamide (5 mL)
was treated with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI)
(0.38 g; 2 mmol), followed by the appropriate amine (2 mmol). The reaction mixture was
stirred at room temperature overnight. The solvent was removed under vacuum and the
residue was added ethyl acetate (30 mL). The organic layer was washed with 5% aqueous
HCl (3 × 10 mL), saturated aqueous NaHCO3 (3 ×10 mL), and brine (10 mL). The organic
layer was dried over anhydrous sodium sulfate. The drying agent was filtered and the
solvent was removed. The crude product was purified by flash chromatography (silica gel/
ethyl acetate/hexanes) to give compounds 10c, 10f, 12a, 12c, 12f and 12i-j.
N-(Furan-2-ylmethyl)-1-oxo-1,2-dihydroisoquinoline-3-carboxamide 10c—White
solid (10% yield), mp 138–140 °C. 1H NMR (DMSO-D6) δ 4.48 (s, 2H), 6.34–6.36 (m, 1H),
6.60–6.62 (m, 1H), 7.35 (s, 1H), 7.57–7.80 (m, 4H), 8.22 (d, J = 8.3 Hz, 1H); HRMS (ESI)
calcd for C15H13N2O3 [M+H]+ 269.0926, found 269.0936; C15H12N2O3Na [M+Na]+
291.0746, found 291.0752.
N-Benzyl-1-oxo-1,2-dihydroisoquinoline-3-carboxamide 10f—White solid(15%
yield), mp 189–191 °C. 1H NMR (CDCl3) δ 4.70 (d, J = 3.5 Hz, 2H), 7.20–7.72 (m, 9H),
8.08 (d, J = 7.7 Hz, 1H), 10.88 (s, 1H); HRMS (ESI) calcd for C17H15N2O2 [M+H]+
279.1134, found 279.1130; C17H14N2O2Na [M+Na]+ 301.0953, found 301.0960.
4-Bromo-N-(3-methoxyphenethyl)-1-oxo-1,2-dihydroisoquinoline-3-
carboxamide 12a—White solid (18% yield), mp 175–177 °C. 1H NMR (CDCl3) δ 2.97
(t, J = 6.9 Hz, 2H), 3.82 (s, 3H), 3.80–3.86 (m, 2H), 6.80–6.89 (m, 3H), 7.23–7.30 (m, 1H),
7.64 (t, J = 7.1 Hz, 1H), 7.67 (s, 1H), 7.79 (t, J = 7.1 Hz, 1H), 8.03 (d, J = 7.4 Hz, 1H), 8.45
(d, J = 7.4 Hz, 1H), 9.78 (s, 1H); HRMS (ESI) calcd for C19H18 35BrN2O3 [M+H]+
401.0501, found 401.0502; C19H18 37BrN2O3 [M+H]+ 403.0480, found 403.0480;
C19H17 35BrN2O3Na [M+Na]+ 423.0320, found 423.0320; C19H17 37BrN2O3Na [M+Na]+
425.0300, found 425.0297.
4-Bromo-N-(furan-2-ylmethyl)-1-oxo-1,2-dihydroisoquinoline-3-carboxamide
12c—White solid (15% yield), mp 197–199 °C. 1H NMR (CDCl3) δ 4.70 (d, J = 4.7 Hz,
2H), 6.37 (s, 2H), 7.41 (m, 1H), 7.64 (t, J = 9.4 Hz, 1H), 7.80 (t, J = 9.4 Hz, 1H), 8.00 (s,
1H), 8.05 (d, J = 9.9 Hz, 1H), 8.42 (d, J = 9.9 Hz, 1H), 9.90 (s, 1H); HRMS (ESI) calcd for
C15H12 35BrN2O3 [M+H]+ 347.0031, found 347.0029; C15H12 37BrN2O3 [M+H]+
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349.0011, found 348.9997; C15H11 35BrN2O3Na [M+Na]+ 368.9851, found 368.9850;
C15H11 37BrN2O3Na [M+Na]+ 370.9830, found 370.9820.
N-Benzyl-4-bromo-1-oxo-1,2-dihydroisoquinoline-3-carboxamide 12f—White
solid (45% yield), mp 208–209 °C. 1H NMR (DMSO-D6) δ 4.48 (d, J = 3.7 Hz, 2H), 7.23–
8.27 (m, 9H), 9.33 (t, J = 3.3 Hz, 1H), 12.10 (s, 1H); HRMS (ESI) calcd for
C17H14 35BrN2O2 [M+H]+ 357.0239, found 357.0236; C17H14 37BrN2O2 [M+H]+
359.0218, found 359.0235; C17H13 35BrN2O2Na [M+Na]+ 379.0058, found 379.0059;
C17H13 37BrN2O2Na [M+Na]+ 381.0038, found 381.0041.
4-Bromo-N-(4-morpholinophenyl)-1-oxo-1,2-dihydroisoquinoline-3-
carboxamide 12i—White solid (10% yield), mp 252–254 °C. 1H NMR (DMSO-D6) δ
3.05–3.15 (m, 4H), 3.70–3.80 (m, 4H), 6.96 (d, J = 7.3 Hz, 2H), 7.56 (d, J = 7.3 Hz, 2H),
7.60–7.68 (m, 1H), 7.84–7.96 (m, 2H), 8.26 (d, J = 6.9 Hz, 1H), 10.82 (s, 1H), 12.17 (s, 1H);
HRMS (ESI) calcd for C20H19 35BrN3O3 [M+H]+ 428.0610, found 428.0625;
C20H19 37BrN3O3 [M+H]+ 430.0589, found 430.0592; C20H18 35BrN3O3Na [M+Na]+
450.0429, found 450.0453; C20H18 37BrN3O3Na [M+Na]+ 452.0409, found 452.0429.
4-Bromo-1-oxo-N-(3-phenoxyphenyl)-1,2-dihydroisoquinoline-3- carboxamide
12j—White solid (33% yield), mp 216–218 °C. 1H NMR (DMSO-D6) δ 6.78 (d, J = 7.4 Hz,
1H), 7.04 (d, J = 7.4 Hz, 2H), 7.13 (d, J = 7.0 Hz, 1H), 7.27–7.40 (m, 3H), 7.46–7.64 (m,
3H), 7.82 (t, J = 7.4 Hz, 1H), 8.00 (d, J = 7.5 Hz, 1H), 8.40 (d, J = 7.5 Hz, 1H), 10.50 (s,
1H), 11.72 (s, 1H); HRMS (ESI) calcd for C22H16 35BrN2O3 [M+H]+ 435.0344, found
435.0340; C22H16 37BrN2O3 [M+H]+ 437.0324, found 437.0341; C22H15 35BrN2O3Na [M
+Na]+ 457.0164, found 457.0155; C22H15 37BrN2O3Na [M+Na]+ 459.0143, found
459.0146.
WNV NS2B/NS3 protease assays (14)—All assays were performed in opaque 96-well
plates. Reaction mixtures (100 μL/assay) contained 200 mM TRIS buffer, pH 9.5, 13.5 mM
NaCl, 30% glycerol, 0.025 μM enzyme, and 100 μM fluorogenic peptide substrate (Boc-
Gly-Lys-Arg-7-amino-4-methyl coumarin). Enzyme incubations were at 25 °C for 30
minutes. The fluorescence of 7-amino-4-methyl coumarin (AMC) released from the
cleavage of the substrate was monitored using excitation and emission wavelengths of 385
nm and 465 nm, respectively.
WNV NS2B/NS3 protease inhibition assays (14)—The protease inhibitor assays
contained 200 mM Tris-HCl buffer, pH 9.5, 13.5 mM NaCl, 30% glycerol, 0.025 μM
enzyme (2.5 pmol), 100 μM fluorogenic peptide substrate and 50 μM inhibitor. The
inhibitors were dissolved in DMSO and diluted in assay buffer. The DMSO concentration in
the assay mix was maintained at 1%, including in the no-inhibitor control. The assay
mixtures containing WNV protease with an inhibitor (or without the inhibitor as a control)
were pre-incubated at room temperature for fifteen minutes. An aliquot of the substrate (100
μM) was added and the incubation continued for an additional fifteen minutes. Fluorescence
values were obtained using excitation and emission wavelengths of 385 nm and 465 nm,
respectively. The percent inhibition of protease activity was determined using Microsoft
Excel. For calculation of IC50 value, in vitro protease assays were performed in triplicate as
described above in the presence of 10, 20, 30, 40 and 50 μM of compound 12j or no-
compound control. The % inhibition (y-axis) was plotted against the concentration of the
inhibitor (x-axis) using GraphPad Prism 5.0 software.
Molecular modeling—Molecular docking simulations were performed via the AutoDock
program (31). Compound 12j was constructed in SYBYL 8.0 (32) and structurally optimized
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to default convergence thresholds using the Tripos Force Field (33) and Gasteiger-Marsili
partial atomic charges (34). The active site model for WNV protease was prepared using the
2FP7 crystal structure (16). The structure was protonated in SYBYL, stripped of all water
molecules and bound ligands, and electrostatically represented with Gasteiger-Marsili
charges. AutoDock simulations were performed using the Lamarckian Genetic Algorithms
(GA) subroutine at default settings for GA population size, cross-over rate and mutation
rate, and starting with fully-randomized ligand position, orientation and conformation. One
hundred GA runs were performed for the ligand-enzyme pair.
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(a) Design of transition state inhibitors (I) based on the 1-oxo-1, 2, 3, 4-
tetrahydroisoquinoline scaffold; (b) Postulated mechanism of action of (I).
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(a) Predicted binding of energy-minimized compound 12j docked to the binding site of
WNV protease. The enzyme surface is colored as follows: red polar O, blue = polar N, cyan
= donatable H, white = mildly polar H/C, yellow = nonpolar H/C/S. (b) Conformer of
compound 12j in the proteolytic active site of WNV protease as predicted by molecular
docking simulations. The ligand is shown as CPK-colored sticks with white carbon atoms,
while a number of key interacting receptor residues are rendered similarly but with green
carbons. The overall structure of the protein is depicted via secondary structure elements
(purple helices, yellow sheets/strands, and cyan coils).
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